A tissue kallikrein has been isolated from rat heart extracts by DEAE-Sepharose and aprotinin-affinity column chromatography. The purified cardiac enzyme has both N-tosyl-L-arginine methyl ester esterolytic and kinin-releasing activities, and displays parallelism with standard curves in a kallikrein radioimmunoassay, indicating it to have immunological identity with tissue kallikrein. The enzyme is inhibited by aprotinin, antipain, leupeptin and by high concentrations of soybean trypsin inhibitor, but stimulated by lima-bean or ovomucoid trypsin inhibitor and low concentrations of soybean trypsin inhibitor. By using a specific monoclonal antibody to tissue kallikrein in Western blot as well as active-site labelling with [14C]di-isopropyl fluorophosphate, the cardiac enzyme was identified as a protein of 38 kDa, a molecular mass identical with that of tissue kallikrein. Immunocytochemistry at the electron-microscopic level localized this enzyme to the sarcoplasmic reticulum and granules of rat atrial myocytes. Two cardiac kallikrein precursors, (38 and 40 kDa) were identified from the translation in vitro of heart mRNA by immunoprecipitation and electrophoresis of [35S]methionine-labelled cell-free translation products. Kallikrein mRNA in the rat heart was also demonstrated by dotblot analysis using a tissue kallikrein cDNA probe. These results indicate that the tissue kallikrein gene is expressed in the rat heart and that the purified enzyme is indistinguishable from tissue kallikrein with respect to enzymic and immunological characteristics.
INTRODUCTION
Tissue kallikreins (EC 3.4.21.35 ) are serine proteinases that cleave kininogen substrates to produce potent vasoactive kinin peptides (Schachter, 1980) . In vitro, kinins are able to cause either smooth-muscle contraction or relaxation depending on the specific target tissue (Johnson, 1979) . Many tissue sites, not previously recognized as kallikrein-containing, have been found to have a proteinase that is enzymically and immunologically identical with the tissue kallikrein in urine, kidney and salivary gland. These sites include spleen , vasculature (Nolly et al., 1985) , pituitary (Powers & Hatala, 1986; Chao et al., 1987) , brain and skeletal muscle (Shimojo et al., 1987) . In addition to kininogen, recent studies have expanded the list of potential natural substrates to include apolipoprotein B-100 (Cardin et al., 1984) , renin (Sealey et al., 1978) , insulin (ole-MoiYoi et al., 1979) and pro-(atrial natriuretic peptide) (pro-ANP) (Currie et al., 1984) . These findings suggest the possibility that kallikreins present in these endocrine and exocrine tissues may have a different functional significance as well as different regulatory mechanisms Nolly et al., 1985; Powers & Hatala, 1986) .
Studies indicate that kinins play an important regulatory role in cardiac function by acting directly on vascular resistance or by inducing prostaglandin release (Needleman et al., 1975) . The kinin-generating system is thought to have a great impact on the pathophysiology of heart disease. Evidence for this is shown in elevated kinin levels in the coronary sinus blood of dogs after occlusion of the anterior descending coronary artery (Kimura et al., 1973) , and also in an activated kinin-generating system observed in the coronary sinus and aortic blood in seven of eleven patients with myocardial ischaemia (Pitt et al., 1970) . Reports have shown that enzymic activity capable of producing kinins from kininogen is present in crude extracts of human, bovine, dog and rat cardiac tissue Britos & Nolly, 1981) ; that the enzyme is tissue kallikrein has not been confirmed. We have recently identified another member of the tissue kallikrein gene family, namely arginine esterase A, in cardiac tissue by immunocytochemistry at the optical-and electron-microscopic level (Simson et al., 1989) . Several recent studies have suggested that the processing enzymes for pro-ANP are present in heart tissues (Cantin & Genest, 1985; Schwartz et al., 1985; Sugawara et al., 1985; Thibault et al., 1986) . The identification of tissue kallikrein in heart, added to our previous findings that exogenous tissue kallikrein in vitro can activate ANP from pro-ANP in rat heart extracts (Currie et al., 1984) , would also support the notion that tissue kallikrein may be one of the regulatory enzymes involved in ANP processing.
The present study describes the identification, isolation and localization of tissue kallikrein in the rat heart and demonstrates kallikrein biosynthesis in the cell-free translation products encoded by heart mRNA.
EXPERIMENTAL

Materials
The following materials were obtained from commercial sources: DEAE-Sepharose CL-6B (Pharmacia); Affi-Gel 10, low-molecular-mass protein standards and prestained molecularmass protein standards (Bio-Rad); bovine serum albumin, bradykinin, sodium deoxycholate, Coomassie Blue and Triton X-100 (Sigma); N-tosyl-L-arginine [3H] Enzyme purification and monoclonal-antibody development Rat urinary or submandibular kallikrein (tissue kallikrein) (Chao & Margolius, 1979) and rat arginine esterase A (Chao, 1983) were purified to homogeneity, and antisera to purified rat kallikreins were generated. Specific monoclonal antibodies to rat tissue kallikrein were developed, characterized and purified along with polyclonal antibodies by kallikrein affinity column chromatography (Woodley et al., 1985) . Purified kallikrein and the affinity-purified monoclonal antibody (V4D11) were labelled with 125I by the lactoperoxidase method (Shimamoto et al., 1980) .
Cardiac kallikrein purification
Step 1: tissue-extract preparation. The rats (Sprague-Dawley; 250 g body wt.) were anaesthetized with pentobarbital (50 mg/ kg). The vena cava was cut and the circulation was perfused via cardiac puncture with normal saline (0.9% NaCI) until tissues appeared blood-free. Heart (both atrium and ventricle) was removed, minced and homogenized in 0.25 M-sucrose, pH 7.0, at 4 'C. Homogenates were centrifuged at 600 g for 8 min, and the supematant was treated with sodium deoxycholate (0.5 % w/v) for 30 min at room temperature. The supernatants were collected after centrifugation at 20000 g for 30 min, and further centrifuged at 105 000 g at 4 'C for 1 h. The supernatants were collected and dialysed against 0.02 M-Tris/HCl, pH 8.0, containing 1 mM-EDTA. The protein concentrations were determined by the Lowry (Lowry et al., 1951) method, bovine serum albumin being used as the standard.
Step 2: DEAE-Sepharose CL-6B chromatography. The dialysed sample was then passed through a DEAE-Sepharose column (2.2 cm x 20 cm) previously equilibrated with the same buffer and washed until the A280 of the effluent fell to below 0.05 unit. Adsorbed proteins were eluted with a linear gradient of NaCl (0-0.6 M). Fractions Step 3: aprotinin-agarose affinity chromatography. The dialysed enzyme solution was applied to an aprotinin-agarose affinity column (Shimamoto et al., 1980 ) equilibrated with 0.2 M-NaCl in 0.02 M-Tris/HCI, pH 8.0. The column was washed with the same buffer until protein was not detected in the effluent. Adsorbed material was eluted with 0.1 M-glycine/HCI, pH 3.0. Fractions (5 ml each) were collected into tubes containing 1 ml of 0.5 MTris/HCl, pH 9.0.
Enzymic activity assays
Kallikrein-like Tos-Arg-OMe esterase activity was measured as described previously (Chao, 1978) . One esterase unit (e.u.) is defined as the amount of enzyme that hydrolyses 1 ,umol of TosArg-OMe/min at pH 8.0 and 30 'C. For the pH-optimum study, the Tos-Arg-OMe esterase activity of the cardiac enzyme was assayed in 0.2 M-Tris/HCI buffer (up to pH 9.0) or 0.2 Mglycine/NaOH buffer (beyond pH 9.0) over the pH range 7.0-10.0. The kininogenase assay (Shimamoto et al., 1979a) was used to determine the kinin-generating activity of the rat cardiac enzyme, and the kinin generated was measured by a kinin radioimmunoassay (Shimamoto et al., 1978) . Purified bovine low-molecular-mass kininogen was used as the substrate. The direct radioimmunoassay of rat tissue kallikrein was carried out as previously described (Shimamoto et al., 1979b) .
Active-site labelling
For active-site labelling, cardiac enzyme (about 4,ug) was incubated with [14C]DFP (0.2 ,uCi; sp. radioactivity > 100 mCi/mmol) in 0.01 M-sodium phosphate, pH 7.0, with a total volume of 30,u for 1 h at 37°C, followed by 16 h at 4°C as previously described . The mixture was then added to 30 ,ul ofextraction buffer containing 0.0625 M-Tris/ HCI, pH 6.8, 200% (v/v) glycerol and 0.2% SDS: SDS/PAGE was performed in a 7.5-150% gradient gel in Tris/glycine buffer, pH 8.8. The gels were fixed and stained for 30 min in 500% (w/v) trichloroacetic acid containing 0.2% Coomassie Blue and destained in solution containing 7 % acetic acid and 18 % methanol. The gels were then treated with EN3HANCE and dried on Whatman no. 3MM filter paper. Fluorography was carried out by placing the gels in direct contact with Kodak XOmat film. The film was developed after 2 days of exposure.
Western-blot analyses
An aliquot of the cardiac enzyme (1 ,ug), submandibular kallikrein (2 jig) or submandibular-gland extract (50,ug) were subjected to SDS/PAGE under reducing conditions on a gradient (7.5-15 %) gel as described above. Proteins were then electrophoretically transferred on to nitrocellulose membrane by using a Trans-Blot Cell (Bio-Rad) as described by Burnette (1981) . The nitrocellulose was incubated in '25I-labelled monoclonal antibodies to tissue kallikrein (V4D11) as described by Woodley et al. (1985) and autoradiographed.
Kallikrein mRNA analysis Total RNA was isolated from whole rat heart by the guanidinium thiocyanate extraction method of Chirgwin et al. (1979) , and dot-blot analysis was performed as described previously . Briefly, RNA samples were denatured in 1 M-glyoxal/10 mM-sodium phosphate, pH 7.0, at 50°C for 1 h. The reaction mixture was cooled and spotted on to nitrocellulose with the aid of a slight vacuum by means of an aspirator. The filtration time was about 1 min for each set of samples. After sample application, the nitrocellulose was dried and baked under vacuum at 80°C for 2 h. It was prehybridized and hybridized at 42°C according to the method of Thomas (1980) , except that the mixture included 10% (w/v) dextran sulphate. A tissue kallikrein cDNA was labelled with 32P by nick-translation to a specific radioactivity of (1-2) x 108 c.p.m./,ug of DNA. The probe was denatured at 100°C for 2 min, cooled, and added to the hybridization buffer at a concentration of (2-3) x 105 c.p.m./ml to hybridize with the blot for about 24 h. The blot was then washed successively for 20 min at 65°C with solutions of 2 x SSC [1 x SSC = standard saline citrate (0.15 M-NaCl/0.015 M-sodium citrate, pH 7.0)], 0.3 x SSC, and 0.1 x SSC containing 0.10% SDS. It was then exposed to Kodak X-Omat AR film.
Translation of heart mRNA in a rabbit reticulocyte system Rabbit reticulocyte lysate was prepared and used as described previously (Roberts & Paterson, 1973 
RESULTS
Purification of tissue kallikrein from rat heart
Rat heart extracts were determined to contain 0.35+0.05ng of kallikrein/mg of protein (mean+ S.E.M., n = 8) by a direct radioimmunoassay. Kallikrein-like activity in the rat heart extracts was monitored by a radiochemical method using TosArg-OMe as the substrate. After dialysis against 0.02 M-Tris/ HCl, pH 8.0, the tissue extract was passed through a DEAESepharos'-CL-6B column. Two peaks of esterolytic activities were elute i from the column with an NaCl gradient. The fractions containin{ tissue kallikrein (the second peak) were eluted at about 0.3 M-NaCl/0.02 M-Tris/HCI, pH 8.0. The pooled fractions were' applied to an aprotinin-affinity column (1.5 cm x 15 cm) equilibrated with 0.2 M-NaCl in 0.02 M-Tris/HCl, pH 8.0. As shown in Fig. 1 , most of the proteins flowed through the column, and the adsorbed esterolytic activity was eluted with 0.1 Mglycine/HCl, pH 3.0.
Enzymic characteristics
Appropriate dilutions of the aprotinin-affinity column eluate were used to obtain a range of antigen concentrations comparable with those of the rat tissue kallikrein standard (0.08-10 ng/tube). Fig. 2 shows typical log-logit transformations of a radioimmunoassay standard curve of rat tissue kallikrein, serial dilutions of the rat cardiac enzyme and rat arginine esterase A (Chao, 1983 (Chao, 1979) , the cardiac enzyme is stimulated by low concentrations of SBTI, and by LBTI or OMTI over a broad range ofconcentrations. The data indicates that cardiac kallikrein and tissue kallikrein have similar susceptibility to various trypsinlike-serine-proteinase inhibitors.
Western-blot analyses In order to determine whether there was specific recognition by a monoclonal antibody to tissue kallikrein, the enzyme isolated from rat heart was subjected to SDS/PAGE under reducing conditions and electrophoretically transferred to the nitrocellulose membrane. In Fig. 4 (Fig. 5) . A lower-molecular-mass 14C-labelled protein band was also revealed that may represent a partially cleaved fragment of cardiac kallikrein. However, this protein band is not recognized by a specific monoclonal antibody to tissue kallikrein (Fig. 4, lane 1) Cell-free translation of rat heart mRNA Cell-free translation products directed by heart mRNA were immunoprecipitated and subjected to SDS/PAGE under reducing conditions. Fig. 6 shows total translation products (lane 1), immunoprecipitates with normal sheep immunoglobulin (lane 2) and immunoprecipitates with affinity-purified sheep anti-(rat urinary kallikrein) antibody (lane 4). Kallikrein antibodies recognized the translation products directed by heart mRNA with molecular-mass values of 38 and 40 kDa. 1251I-labelled rat urinary kallikrein is shown in lane 3.
Dot-blot analysis of tissue kallikrein mRNA in rat heart Fig. 7 shows the results of dot-blot hybridization with a kallikrein cDNA. The intensities of signals from heart are slightly higher than those from liver (results not shown) when using equal amounts of RNA. The combined data from RNA hybridization of dot-blot analysis and the kallikrein synthesis in cell-free translation system indicate the existence of kallikrein mRNA in the heart. As positive controls, kallikrein mRNA were also identified in other tissues, such as kidney, spleen and pancreas, sites known to synthesize tissue kallikrein ). Cell-free translation products were electrophoresed on a 7.5-15% linear-gradient polyacrylamide/SDS gel after immunoprecipitation. Lane 1, total cell-free translation products; lane 2, translational products immunoprecipitated with normal sheep IgG; lane 3, 125I-labelled rat tissue kallikrein; lane 4, translational products immunoprecipitated with affinity-purified sheep anti-(rat tissue kalliicrein) antibody. Fig. 7 . Dot-blot analyses of kallikrein mRNA in rat heart and other tissues Total RNA was extracted from various tissues and dotted on to nitrocellulose. The kallikrein mRNA in each spot was measured by hybridization to 32P-labelled rat tissue-kallikrein cDNA probe, followed by exposure of the nitrocellulose blot to X-ray film. Serial dilution of total RNA was performed: 1, 40 jg; 2, 20ug; 3, 10 ,ug; 4, 5 ug.
Immunocytochemical localization At the electron-microscopic level, immunostaining using the specific monoclonal antibody (V4D,,) for tissue kallikrein was observed primarily in regions between myofibrils that correspond to sites of sarcoplasmic reticulum of rat atrial myocytes (Fig. 8a) . The most intense labelling was seen near the cell periphery, beneath the membrane. A low level of staining was also localized in atrial granules with this antibody. In sites where T-tubules were recognizable, immunostaining was not seen within the tubule, but was present nearby. The control sections showed low background staining when normal mouse ascitic fluid was used in place of the primary antibody (Fig. 8b) .
DISCUSSION
The present report describes the first demonstration that tissue kallikrein mRNA and protein are present in rat heart. The cardiac enzyme was isolated from rat heart extracts by DEAE-Sepharose and aprotinin-affinity column chromatography and shown to be an active serine proteinase with both Tos-Arg-OMe esterase and kininogenase activities. The enzyme is indistinguishable from tissue kallikrein and clearly differentiable from other members of the kallikrein gene family with respect to molecular mass, charge, immunological properties, pH optimum, substrate specificity and susceptibility to inhibitors. Furthermore, it is recognized by a specific monoclonal antibody to purified tissue (urinary) kallikrein which does not cross-react with arginine esterase A, tonin or other kallikrein-like enzymes (Woodley et al., 1985) .
Molecular analysis of the kallikrein gene products was initiated by examining the primary biosynthetic products directed by total RNA from rat heart in a cell-free translation system. .
By using electron microscopy the subcellular localization of tissue kallikrein was examined with a specific monoclonal antibody to tissue kallikrein. With the calcium acetate-buffered paraformaldehyde fixative used in the present study, membranes were poorly preserved. The fact that positive staining was mainly localized between myofibrils at the cellular sites of sarcoplasmic reticulum, and to a lesser extent, in granules, suggests a functional diversity of tissue kallikrein in the heart. Previously, we have localized another kallikrein-like enzyme, namely arginine esterase A (Chao, 1983) , in rat heart at both the optical-and electronmicroscopic level and have co-localized arginine esterase A with pro-ANP in granules of atrial myocytes by double-label electronmicroscopic immunocytochemistry (Simson et al., 1989) . The functional roles of these two related enzymes in the heart has yet to be determined, although both have been shown to release ANP from prohormone in vitro (Currie et al., 1984; Simson et al., 1989) .
Recent studies have reported several potential processing enzymes of ANP in bovine, porcine and rat heart Wypij & Harris, 1987; Imada et al., 1988) . A tissuekallikrein-like enzyme has been implicated in the catabolism of ANP (Thibault et al., 1983) . Our previous studies showed that tissue kallikrein is capable of processing pro-ANP to produce the active form in vitro (Currie et al., 1984) and that the activation can be abolished by aprotinin, a potent inhibitor of tissue kallikrein. Studies suggested that pro-ANP is converted into the active form during, or just after, secretion from the atrium (Cantin & Genest, 1985; Schwartz et al., 1985; Sugawara et al., 1985; Thibault et al., 1986 ). The present study shows the localization of tissue kallikrein in the atrial myocytes, where active ANP is formed. Although the relationship between tissue kallikrein and ANP is unknown, together these findings suggest that cardiac kallikrein is a candidate for one of the regulatory factors in pro-ANP processing or ANP metabolism.
Tissue kallikrein releases vasoactive substances, kinins, which are known to regulate local blood flow within the heart through its effect on coronary arteries (Lochner & Parratt, 1966) . This has also been demonstrated in studies showing increased kinin-like activity in dog coronary sinus blood after coronary-artery occlusion (Kimura et al., 1973) , a condition resembling coronary heart disease. Furthermore, activation of kallikrein-like enzymic activity has been reported in coronary sinus blood of patients with myocardial ischaemia (Pitt et al., 1970) . A recent study (Scholkens & Linz, 1989) has shown that, in isolated perfused working rat hearts with regional myocardial ischaemia, bradykinin, in concentrations as low as 1 nM, increased coronary flow and reduced the incidence and duration of the ventricular fibrillation following reperfusion. In addition, the venous effluent of these hearts showed reduced lactate dehydrogenase and creatine kinase activities and decreased lactate output as well as improved cardiodynamic and metabolic parameters. These effects could be competitively reversed by specific bradykinin antagonists (Scholkens & Linz, 1989) . These findings suggest that the kinin system may play an important role in pathological conditions such as ischaemic heart disease and/or act as a protective or compensatory system by increasing the blood supply to cardiac tissue through vasodilatation. Tissue kallikrein, which produces kinins from kininogen, may be one of the key factors in the regulation of this system. Further studies need to be carried out to elucidate the role of cardiac kallikrein, especially in conditions like ischaemic heart diseases. This work was supported by National Institutes of Health grant HL29397.
